Drawing for NYZUMSA

USPTO serial 79302146

NYZUMSA

Reviewed by CopyMark Law Group

Status 401
Filing date
Status date
Registration date
Examiner
JACKSON, WILLIAM D
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NYZUMSA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccinesSECTION 70 - CANCELLED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 4, 2021DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Jul 3, 2021DETHDEATH OF INTERNATIONAL REGISTRATION
Jun 8, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 19, 2021NPUBNOTICE OF PUBLICATION
Apr 30, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Apr 30, 2021DOCKASSIGNED TO EXAMINER
Jan 23, 2021MAFRAPPLICATION FILING RECEIPT MAILED
Jan 19, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 15, 2021LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 14, 2021REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance